New cancer drug enters first human trials
NCT ID NCT06779851
Summary
This is the first study in humans of a new immunotherapy drug called BPT567 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, check for side effects, and see how the body processes the drug. Researchers will also look for early signs that the drug might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
Hackensack Meridian John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Honor Health Research Institute
Scottsdale, Arizona, 85260, United States
-
Providence Cancer Institute
Portland, Oregon, 97213, United States
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
Start Midwest
Grand Rapids, Michigan, 49546, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.